What is Exagen?
Exagen is a United States-based life sciences enterprise dedicated to the development and commercialization of advanced diagnostic testing solutions. By focusing on the complex landscape of autoimmune and rheumatic diseases, the company provides healthcare providers with critical insights through its proprietary AVISE brand. Utilizing innovative biomarkers and sophisticated testing technologies, Exagen bridges the gap between clinical uncertainty and actionable treatment strategies. Its patient-centered approach is designed to improve the accuracy and timing of disease detection, particularly for conditions such as lupus and rheumatoid arthritis, thereby enhancing long-term clinical outcomes through research-driven diagnostic innovation.
How much funding has Exagen raised?
Exagen has raised a total of $258.3M across 15 funding rounds:
Series D
$5M
Debt
$25M
Debt
$4M
Debt
$1.8M
Debt
$3M
Series E
$16.8M
Debt
$2.1M
Series F
$23M
Debt
$25M
Private Equity
$22.6M
Stock Offering
$58M
Stock/Share Issuance
$20.2M
Series D (2013): $5M featuring CRG L.P.
Debt (2013): $25M backed by Capital Royalty Partners
Debt (2014): $4M with participation from Sun Mountain Capital
Debt (2015): $1.8M, investors not publicly disclosed
Debt (2015): $3M, investors not publicly disclosed
Series E (2016): $16.8M, investors not publicly disclosed
Debt (2016): $2.1M, investors not publicly disclosed
Series F (2017): $23M, investors not publicly disclosed
Debt (2017): $25M led by Innovatus Capital Partners, LLC
Private Equity (2019): $22.6M supported by H.I.G. BioHealth Partners, Tullis Health Funds, Hunt Holdings, and Sun Mountain
Stock Issuance/Offering (2019): $58M featuring Undisclosed
Stock/Share Issuance (2025): $20.2M, investors not publicly disclosed
Key Investors in Exagen
Tullis Health Investors
Tullis Health Investors is a private equity firm that specializes in investing in high-growth, commercial-stage healthcare companies across various sectors including medical devices, healthcare services and technology, specialty pharmaceuticals, and biotechnology.
Sun Mountain Capital
Founded in 2006, Sun Mountain Capital is a private equity firm with investment strategies in both direct investment and fund of funds programs spanning venture capital, private credit and growth equity.
H.I.G. BioHealth Partners
H.I.G. Capital is a global alternative investment firm providing debt and equity capital to small and middle-market companies through funds focused on private equity, growth equity, and healthcare.
What's next for Exagen?
The latest infusion of capital positions Exagen to further refine its diagnostic portfolio and expand its reach within the competitive life sciences market. As the company transitions through its current lifecycle stage, the focus is expected to shift toward scaling operational efficiencies and deepening its penetration in the autoimmune diagnostics space. By leveraging its established technological foundation, Exagen is well-positioned to capitalize on the increasing demand for precision medicine and personalized healthcare solutions, ensuring that its diagnostic tools remain at the forefront of clinical decision-making.
See full Exagen company page
